Global CRO ICON plc, a provider of drug and device development and commercialization services to clinical sponsors announced the acquisition of MeDiNova Research, a site network with research sites in targeted markets in Europe and Africa. ICON, in competing against other global CRO operations, enhances its patient outreach and positioning in targeted geographies.
Who is MeDiNova?
Founded in 2000 with a headquarter office in Coventry, UK, they are a network of 33 active clinical research sites in the UK, Spain, South Africa, Poland and Romania. With its ability to operate different site models depending on sponsor needs—from dedicated research sites to integrated research sites to partnerships with affiliate sites—they have experience across a wide range of clinical experience with emphasis on the following:
- Infectious disease
- General health
- Vaccine studies
MeDiNova Research is a global network of quality research sites, providing investigator based clinical research services to the pharmaceutical and biotech industry. The company is a specialist in Phase II-IV clinical studies in multiple therapeutic areas and has outstanding global experience and expertise in the delivery of quality clinical research. Headquartered in Coventry, United Kingdom, MeDiNova Research currently operates from 33 active clinical research sites in five countries and has approximately 160 employees.
This acquisition further enhances ICON’s existing site network in the U.S.: PMG Research.
About ICON plc
ICON plc is a global provider of outsourced drug development and commercialization solutions and services to the pharmaceutical, biotechnology, medical device and government and public health organizations. The company specializes in the strategic development, management and analysis of programs that support clinical development—from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 90 locations in 37 countries and has approximately 13,920 employees.